Minerva Biotechnologies Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Minerva Biotechnologies's estimated annual revenue is currently $4.2M per year.(i)
  • Minerva Biotechnologies's estimated revenue per employee is $155,000

Employee Data

  • Minerva Biotechnologies has 27 Employees.(i)
  • Minerva Biotechnologies grew their employee count by 0% last year.

Minerva Biotechnologies's People

NameTitleEmail/Phone
1
Founder and CEO.Reveal Email/Phone
2
COOReveal Email/Phone
3
Head Research And DevelopmentReveal Email/Phone
4
Group Leader, Stem Cell BiologyReveal Email/Phone
5
Research ScientistReveal Email/Phone
6
Stem Cell Research ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Minerva Biotechnologies?

Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies. Both flow from Minerva's fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1*. -Cancer Therapeutics- Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline. -Regenerative Medicine- Minerva is the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, and are more easily directed to develop into functional mature cells, which could be used for transplant.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Minerva Biotechnologies News

2022-04-06 - Global Mucin 1 Market 2022-2028 Regional Analysis, Types ...

Minerva Biotechnologies Corp; Transgene SA; Vaxil Bio Therapeutics Ltd. The region included in the report: North America (United States, Canada,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M2713%N/A
#2
$2.7M270%N/A
#3
$2.6M27N/AN/A
#4
$4.4M288%N/A
#5
$5.3M280%N/A